FOLFOXIRI is a chemotherapy regimen for the treatment of advanced colorectal cancer.FOLFOXIRI plus bevacizumab (bev) versus FOLFIRI plus bev as first-line treatment of metastatic colorectal cancer (mCRC): Updated survival results of the phase III TRIBE trial by the GONO group. J Clin Oncol 33, 2015 (suppl 3; abstr 657) ESMO. First-Line FOLFOXIRI/Bevacizumab Improves Long-Term Outcomes in Metastatic Colorectal Cancer. Updated survival results of the phase III TRIBE study. The role of FOLFOXIRI in colorectal cancer has been reviewed.
The chemotherapy regimen is made up of the following four drugs:
FOL – folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F – fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; OX – oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis; IRI – irinotecan (Camptosar), a topoisomerase inhibitor, prevents DNA from uncoiling and duplicating.
It is usually given with bevacizumab, unlike FOLFIRINOX for treatment of advanced pancreatic cancer. Also, the doses (Day 1: irinotecan 165 mg/m2 IV, plus oxaliplatin 85 mg/m2 IV; Day 1: leucovorin 400 mg/m2; Days 1–3: fluorouracil 1,600 mg/m2/day × 2 days (total 3,200 mg/m2 over 48 hours) continuous infusion starting on day 1; Day 1: bevacizumab 5 mg/kg IV; repeat cycle every 2 weeks) are slightly dissimilar to FOLFIRINOX.
Upfront FOLFOXIRI with bevacizumab can be followed by fluoropyrimidine with bevacizumab maintenance.
See also FOLFIRI FOLFOX FOLFIRINOX IFL
References